# Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer

> **NCT01589367** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 208 (actual)

## Conditions studied

- Hormone Receptor Positive Malignant Neoplasm of Breast

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01589367
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2018-04
- **Final completion:** 2018-08
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589367, "Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01589367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*